CMS Retires NCD 220.6.3 for FDG PET in Esophageal Cancer — What Billing Teams Need to Know
CMS has officially retired NCD section 220.6.3, which previously governed Medicare coverage for FDG PET imaging in esophageal cancer, under policy code NCD 293 (policy key 293-v3). This change, effective March 12, 2026, consolidates FDG PET esophageal cancer coverage guidance under the broader PET scan NCD at section 220.6.17. If your facility bills Medicare for PET imaging in oncology—particularly gastrointestinal cancers—this structural change has real implications for how you reference coverage criteria and document medical necessity.
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | FDG PET for Esophageal Cancer (Replaced with Section 220.6.17) — RETIRED |
| Policy Code | NCD 293 |
| Change Type | Modified |
| Effective Date | 2026-03-12 |
| Impact Level | Medium |
| Specialties Affected | Radiology, Nuclear Medicine, Oncology, Gastroenterology, Thoracic Surgery |
| Key Action | Update all internal coverage reference documents and medical necessity templates to cite NCD 220.6.17 instead of 220.6.3 for FDG PET esophageal cancer claims. |
What Changed: CMS NCD 220.6.3 for FDG PET Esophageal Cancer Is Now Retired
The Centers for Medicare & Medicaid Services has formally removed section 220.6.3 from the NCD Manual. This section had served as the standalone coverage determination for FDG PET scans used in the staging, restaging, and management of esophageal cancer. Its retirement is not a coverage elimination—it's a consolidation.
Coverage guidance for FDG PET in esophageal cancer now lives under NCD section 220.6.17, which is part of the broader PET Scans NCD (§220.6). The retirement of 220.6.3 has been in effect since April 3, 2009 at the clinical policy level, but the March 2023 revision (Rev. 11892, issued 03-09-23, effective 04-10-23) formally removed the section from the NCD Manual. The 2026 effective date on this record reflects the latest administrative update to NCD 293's version tracking.
For billing and revenue cycle teams, the practical impact is this: any internal documentation, payer policy crosswalks, or medical necessity templates that cite section 220.6.3 as the coverage authority for FDG PET esophageal cancer claims are now pointing to a retired, removed section of the NCD Manual.
Understanding the Policy Structure: NCD 220.6 and the PET Scan Framework
Medicare's coverage for PET scans is organized under the umbrella NCD at §220.6, which governs FDG PET imaging across a wide range of oncologic and non-oncologic indications. Sub-sections within 220.6 address specific cancer types and clinical scenarios.
Section 220.6.17 is now the authoritative reference for FDG PET coverage in esophageal cancer under Medicare. Billing teams should pull the current language from the CMS Medicare Coverage Database directly at the cross-referenced NCD for PET Scans (§220.6) to confirm applicable medical necessity criteria, coverage conditions, and any limitations that govern esophageal cancer-specific claims.
The benefit category for this service remains Diagnostic Tests (other) under Medicare Part B. Claims submitted without proper alignment to the current NCD section risk medical necessity denials—particularly if MAC local coverage policies or internal payer crosswalk tools haven't been updated to reflect the active section.
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
Affected Codes
The policy data for NCD 293 (policy key 293-v3) does not list specific CPT, HCPCS, or ICD-10 codes. No codes are enumerated in this retired NCD record.
For applicable billing codes associated with FDG PET imaging in esophageal cancer, you must reference the active NCD at §220.6.17 and the cross-referenced PET Scans NCD (§220.6) directly in the CMS Medicare Coverage Database. Relevant procedure codes for FDG PET studies—including both the professional and technical components—are governed by the active PET scan NCD, not this retired section.
If your billing team has historically used this NCD record as a code lookup source, that workflow needs to change immediately. The retired section carries no active code list.
Why This Matters for Revenue Cycle Teams in 2026
Retiring a section from the NCD Manual sounds administrative, but the downstream billing consequences are real. Here's where teams typically run into trouble:
Prior authorization workflows. Some health systems and hospital outpatient departments have prior auth templates that reference specific NCD sections as the coverage basis. If your PA submission template cites 220.6.3, a savvy payer reviewer—or an automated system—may flag the outdated reference.
Denial management. Appeals for denied FDG PET claims in esophageal cancer patients need to cite the correct NCD authority. An appeal citing a retired, removed NCD section weakens your argument, even if the clinical facts fully support coverage.
Compliance documentation. If your compliance program maintains a policy library that maps clinical services to their NCD/LCD authority, that map has a broken link. Internal audits and third-party compliance reviews will catch this.
Coder education. Coders and clinical documentation specialists who work in oncology—particularly for esophageal, GI, and thoracic cases—should know that the authoritative Medicare coverage reference for FDG PET in esophageal cancer is now §220.6.17.
What Your Billing Team Should Do
| # | Action Item |
|---|---|
| 1 | Immediately update your internal NCD crosswalk and policy library — Replace all references to NCD section 220.6.3 with section 220.6.17 as the active Medicare coverage authority for FDG PET in esophageal cancer. Do this before the March 12, 2026 effective date to avoid any claim submission gaps. |
| 2 | Pull and review the current language of NCD §220.6.17 — Access the active PET Scans NCD directly through the CMS Medicare Coverage Database (linked via §220.6). Confirm what medical necessity criteria, coverage conditions, and any oncologic indication-specific limitations apply to esophageal cancer claims under the consolidated section. |
| 3 | Audit open and pending prior authorization requests — Review any active PA submissions for FDG PET studies in esophageal cancer patients to confirm they reference the correct NCD authority. Resubmit or supplement any that cite the retired 220.6.3 section. |
| 4 | Update denial appeal templates — Revise any appeal letter templates or medical necessity argument frameworks that reference 220.6.3 as the coverage basis. Appeals submitted after the effective date should cite §220.6.17 exclusively. |
| 5 | Brief your oncology coding and billing staff — A short internal communication to coders, billers, and utilization review staff covering the NCD section change will prevent downstream errors. This is especially important for teams that handle high volumes of esophageal, gastroesophageal junction, or thoracic oncology cases. |
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.